Hester Bios Q1 FY27 Earnings Call — Analysis (NSE: HESTERBIO)
Standalone profitability surges on poultry demand and margin expansion; consolidated net profit boosted by exceptional loan waiver gain
The take
Q1FY27 Consolidated Revenue ₹77.24 Cr ( -8% YoY ) . New story: Poultry outperformance as a growth driver .
Results
Standalone revenue grew 14% YoY with PAT up 88% and EBITDA up 95%; gross margin improved from 69% to 78%. Consolidated revenue declined 8% due to lower Nepal/Africa revenues but net profit of ₹96.73 Cr included an exceptional gain from amendment of the Gates Foundation soft loan.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹77.24 Cr | -8% | yoy · Q1FY27 |
| Consolidated Net Profit | ₹96.73 Cr | point_in_time · Q1FY27 · includes exceptional gain from Gates Foundation loan amendment | |
| Standalone Revenue Growth | +14% | yoy · Q1FY27 · standalone | |
| Standalone PAT Growth | +88% | yoy · Q1FY27 · standalone | |
| Standalone EBITDA Growth | +95% | yoy · Q1FY27 · standalone | |
| Standalone Gross Margin | 78% | yoy · Q1FY27 · improved from 69% in Q1FY26 | |
| Poultry Healthcare Division Revenue Growth | +48% | yoy · Q1FY27 · poultry healthcare division | |
| Consolidated Debt | ₹103 Cr | point_in_time · Q1FY27 · as on 30th June 2026, post Gates Foundation loan amendment |
What management committed to
- The delayed government vaccine tender business for [PPR eradication and Lumpy Skin Disease Control Initiative] will come up into the next quarter (Q2FY27). — Q2FY27
Key themes
Poultry division outperformance and operational efficiency gains
How the narrative shifted
- Poultry outperformance as a growth driver: Management attributes strong poultry growth to market share gains, deeper penetration, new health products, and a holistic disease prevention approach, while vaccine prices remain stable.
- Animal health dependent on tender cycles: Animal healthcare revenues suffer from government tender timing delays (PPR/ LSD) but management insists this is temporary and demand remains intact; they are also building direct dairy farm demand.
- International operations a long-term bet: Africa and Nepal revenues remain low due to geopolitical, financial, and formative-stage challenges; Gates Foundation loan waiver seen as an endorsement of long-term mission.
- Operational efficiency and margin expansion: Gross margin jump from 69% to 78% and 95% EBITDA growth reflect product mix improvements and cost discipline; management stresses this momentum will be maintained.
- Innovation pipeline as future catalyst: Regulatory dossiers submitted, Brucella recombinant vaccine progressing, but no launch timelines; BSL3 facility provides platform for advanced biologicals.
- Disciplined capital allocation and debt reduction: Consolidated debt reduced to ₹103 Cr; management highlights positive operating cash flow and refutes cash conversion concerns.
Operational commentary
- Poultry Healthcare Division achieved 48% YoY growth driven by higher institutional business, deeper market penetration, and new health products (feed supplements, disinfectants) complementing vaccines.
- Avian influenza low-path vaccine (approved March 2026) saw good market response and contributed to poultry revenue jump.
- Animal Healthcare Division remained subdued due to timing of government-led immunization programs (PPR, Lumpy Skin Disease) – a temporary delay, not a demand issue.
- Gates Foundation amended Hester Africa loan: principal reduced from USD 12 mn to USD 5 mn, accrued interest waived, loan made interest-free, reflecting continued mission support.
- BSL3 facility and fill-finish plant operational; utilisation being ramped up but no target percentage given; management committed to optimal utilisation for pipeline veterinary products.
- Pet care division emerging, offering antibiotics, anti-parasitics, grooming products; not yet separately reported; management aims for domestic manufacturing-led model, refusing import-only play.
- Consolidated debt reduced to ₹103 Cr post loan amendment; management says operating cash flow positive and receivables manageable.
Analyst Q&A
Q. Implications of recent Ministry meeting on high pathogenic avian influenza and potential vaccine import/testing for Hester
Priya Gandhi: At this point it is premature to comment. The government needs to determine regulatory pathway – import or local manufacture. We are monitoring but cannot speculate.
Q. Concern about weak cash conversion – reported profit not backed by operating cash flow
Rajiv Gandhi and Ashish Desai: Cash flow is positive, receivables are a little higher due to seasonal trends, not a concern or red flag.
Q. Timeline for launch of pet vaccines in the pet care business
Priya Gandhi: Premature to say; products are progressing, but regulatory timelines are stringent. We will share developments as they reach appropriate stages.
Research and educational content only. Not investment advice.